BridgeBio Oncology has entered a definitive merger agreement with Helix Acquisition Corp II, which will result in the ...

The deal comes amid an uptick in so-called SPAC deals, which had fallen out of favor due to poor returns and increased ...

Clinical-stage BridgeBio Oncology Therapeutics, whose financial backers include Cormorant Asset Management, is going public ...

In a move straight out of 2021, BridgeBio Oncology is taking the SPAC route to the public markets in a deal with Helix ...

BridgeBio Oncology Therapeutics (BBOT), a company advancing small molecule therapeutics targeting RAS and PI3Ka malignancies, ...

BridgeBio Pharma (BBIO) stock in focus as its 2024 spinout BridgeBio Oncology merges with Helix to form go public on Nasdaq ...

BridgeBio Oncology Therapeutics, a company working to advance the field of therapies addressing a validated but elusive group of cancer targets, has reached a deal to go public in a SPAC merger ...

BridgeBio Oncology Therapeutics, a cancer drug startup spun out of biotechnology company BridgeBio Pharma, will go public by merging with a blank-check entity. In a deal announced Friday ...

For a while, special purpose acquisition companies were biotech’s hot ticket to the public markets. | For a while, special ...

One year after its initial public offering, Helix Acquisition Corp. II is now helping another biotech company go public.

Odine, a global technology partner, takes another significant step in its global expansion journey by establishing OdineLabs ...